Valeant Pharma (VRX) Reports Q2 Loss of $0.11, Adj-EBITDA Beats; Maintains FY EPS, Lowers FY Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Announces Second-Quarter 2017 Results
August 8, 2017 7:00 AM EDTLAVAL, Quebec, Aug. 8, 2017 /PRNewswire/ --
Second-Quarter 2017 Financial Results Revenues of $2.233 Billion GAAP Net Loss of $38 Million Adjusted Net Income (non-GAAP) of $362 Million Year-to-Date GAAP Cash Flow from Operations of $1.222 Billion Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 Million Delivered Strong Organic Growth1Â (non-GAAP) in Bausch + Lomb/International Segment and Salix Business Expects to Exceed $5 Billion Debt Reduction Commitment Early Updates 2017 Full-Year Revenue Guidance Range and Maintains 2017 Full-Year Adjusted EBITDA (non-GAAP)... More